ANVS 9.22 Annovis Bio, Inc.
| Range: | 4.53-22.49 | Vol Avg: | 257495 | Last Div: | 0 | Changes: | 0.55 |
| Beta: | 1.72 | Cap: | 0.12B | Currency: | USD | Exchange: | NYSE |
| Sector: | Healthcare | IPO: | Wed Jan 29 2020 | Empoloyees: | 6 | ||
| CUSIP: | 03615A108 | CIK: | 0001477845 | ISIN: | US03615A1088 | Country: | US |
| CEO: | Dr. Maria L. Maccecchini Ph.D. | Website: | https://www.annovisbio.com | ||||
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Stock Details
ANVS 30
H.C. Wainwright Reiterates Buy Rating on Annovis Bio Inc. (ANVS)
Raghuram Selvaraju·Wed Oct 16 2024
H.C. Wainwright
ANVS 21
Annovis Bio initiated with a Buy at EF Hutton
Jason Kolbert·Tue Aug 13 2024
EF Hutton
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow